

Approved



**Rwanda**  
**Country Operational Plan**  
**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		133,004		133,004	0	133,004
USAID		35,168,971		35,168,971	2,561,096	37,730,067
DOD		1,091,497		1,091,497	1,142,380	2,233,877
PC		0		0	497,681	497,681
HHS/CDC	1,440,625	27,792,157		29,232,782	1,955,872	31,188,654
State/PRM		216,717		216,717	0	216,717
<b>Total</b>	<b>1,440,625</b>	<b>64,402,346</b>	<b>0</b>	<b>65,842,971</b>	<b>6,157,029</b>	<b>72,000,000</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold Amount	Total
	State	DOD	HHS/CDC	PC	State/PRM	USAID		
CIRC		168,020	52,024			225,870	0	445,914
HBHC	2,660	10,643	1,793,451		11,126	1,238,572	0	3,056,452
HKID						5,316,723	0	5,316,723
HLAB		74,722	1,636,185			362,568	0	2,073,475
HMBL			0			0	0	0
HMIN			0			0	0	0
HTXD						16,312,149	0	16,312,149
HTXS	2,660	382,902	11,236,583		89,007	6,392,704	0	18,103,856
HVAB						0	0	0
HVCT		294,185	2,546,393		35,834	1,205,039	0	4,081,451
HVMS	117,044	0	2,971,577	0		898,892	0	3,987,513
HVOP	2,660	132,498	568,609		44,079	654,992	0	1,402,838

Approved



HVSI	2,660	8,897	2,330,561			22,283	0	<b>2,364,401</b>
HVTB		0	1,029,860		11,126	0	0	<b>1,040,986</b>
IDUP						0	0	<b>0</b>
MTCT		16,486	1,934,984		17,144	204,135	0	<b>2,172,749</b>
OHSS	2,660		795,591			1,534,691	0	<b>2,332,942</b>
PDCS	2,660	1,572	541,630		3,108	461,158	0	<b>1,010,128</b>
PDTX		1,572	1,795,334		5,293	339,195	0	<b>2,141,394</b>
	<b>133,004</b>	<b>1,091,497</b>	<b>29,232,782</b>	<b>0</b>	<b>216,717</b>	<b>35,168,971</b>	<b>0</b>	<b>65,842,971</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	2,978,069	0
HKID	5,294,420	0
HVTB	991,193	0
PDCS	983,128	0
<b>Total Technical Area Planned Funding:</b>	<b>10,246,810</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	1,568,751	0
HVSI	1,202,231	0
OHSS	1,809,384	0
<b>Total Technical Area Planned Funding:</b>	<b>4,580,366</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	435,090	0
HMBL	0	
HMIN	0	
HVCT	4,023,831	0
HVOP	1,350,505	0
MTCT	2,130,750	0
<b>Total Technical Area Planned Funding:</b>	<b>7,940,176</b>	<b>0</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	16,284,488	0
HTXS	18,016,173	0
PDTX	2,100,046	0
<b>Total Technical Area Planned Funding:</b>	<b>36,400,707</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	132,877
	Number of new ANC and L&D clients	135,534
	By: Known positives at entry	2,743
	By: Number of new positives identified	1,100
	Sum of Positives Status disaggregates	3,843
	Required only for DREAMS Countries - By Number of new positives: <15	
	Required only for DREAMS Countries - By Number of new positives: 15-19	
	Required only for DREAMS Countries - By Number of new positives: 20-24	
	Required only for DREAMS Countries - By Number of known positives: <15	
	Required only for DREAMS Countries - By Number of known	



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	
	Required only for DREAMS Countries - Denominator: <15	
	Required only for DREAMS Countries - Denominator: <15-19	
	Required only for DREAMS Countries - Denominator: 20-24	
	Required only for DREAMS Countries - Denominator: 25-49	
	Required only for DREAMS Countries - Denominator: 50+	
	Required only for DREAMS Countries - By Number of known positives: 25-49	
	Required only for DREAMS Countries - By Number of known positives: 50+	
	Required only for DREAMS Countries - By Number of new positives: 25-49	
	Required only for DREAMS Countries - By Number of new positives: 50+	
	By Age (DREAMS SNU's ONLY): <15	
	By Age (DREAMS SNU's ONLY): 15-19	
	By Age (DREAMS SNU's ONLY): 20-24	
	By Age (DREAMS SNU's ONLY): 25-49	



	By Age (DREAMS SNU's ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	132,877
	New on ART	1,172
	Already on ART at beginning of current pregnancy	2,490
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	95,936
	By Age: 0-60 days	
	By Age: 2 months - 9 years	
	By Age: 10-14	3,196
	By Age: 15-19	36,012
	By Age: 20-24	30,375
	By Age: 25-29	21,456
	By Age: 30-49	4,701
	By Age: 50+	188
	Sum of age disaggregates (Prior to FY15)	69,771
	Sum of age disaggregates (FY15-Current)	95,928
By HIV status: Number of		





	HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	38,272
	By circumcision technique: Device-based VMMC	57,462
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,895
	Total number of people in the	15,868



	target population	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	0
	Aggregated Age/sex: 15+ Male	6,185



	Aggregated Age/sex: <15 Female	761
	Aggregated Age/sex: 15+ Female	6,949
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	9,311
	Total estimated number of key population in the catchment area	9,331
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	737
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual	0



	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8,574
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0



	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	737
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	8,594
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the	0



	catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	957,298
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	



	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
	Test Result by Age and Sex: Positive: 20-24 Female	
	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex:	



	Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	39,348
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	409,805
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	38,865
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	471,783
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	169
	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,063
	Test Result by Aggregated Age and Sex: Positive <15 Female	198
	Test Result by Aggregated Age	7,486





	and Sex: Positive 15+ Female	
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	3,011
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	92,041
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	14,068
	Service Delivery Point (Facility): Outpatient	215,928
	Service Delivery Point (Facility):	0



	Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	106,027
	Service Delivery Point (Facility): VCT	283,573
	Service Delivery Point (Facility): VMMC	85,280
	Service Delivery Point (Facility): PMTCT	133,475
	Service Delivery Point (Facility): TB Clinics	2,624
	Service Delivery Point (Facility): Index testing	7,555
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by	



	Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,774
	Total number of registered new and relapsed TB cases, during the reporting period.	2,774
	Age/Sex: <1 (Numerator: Number	



	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	86
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,695
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52



	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	940
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and	



	relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	5,789
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <10 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Sum of Age/Sex Disaggregates	
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,679
By type of service: Sexual Violence (Post-Rape Care)	4,108	
By PEP service provision (related to sexual violence services provided)	1,332	
Age/Sex: 15-19 Female		
Age/Sex: 15-19 male		
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	121,229





	HIV/AIDS	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	19,227
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	24,377
	Sum of Age/Sex disaggregates	43,604
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	



	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



	Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	



	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	



	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	



	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	36,703
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	40,922
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and	916



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	916
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented	





	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	



	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	19
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	574
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
	Aggregated Age/Sex: Female 15+ (Numerator: The number of	315



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	101,816
	Screened for TB by Age/Sex:<15 Male	2,589
	Screened for TB by Age/Sex: 15+ Male	35,054
	Screened for TB by Age/Sex:<15 Female	2,549
	Screened for TB by Age/Sex: 15+ Female	61,627
	Screen Result: Screened Positive for TB	8,964
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	9,258
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	6,425
	[Sub-Disagg of Specimen Sent]	2,842



	Diagnostic Test: Xpert MTB/RIF assay	
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	3,479
	By infants who received their first virologic HIV test between 2 and 12 months of age	195
	Sum of Infant Age disaggregates	3,674
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	44
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2	



	and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	104,054
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	2,616
	Aggregated Age/Sex: 15+ Male	35,919
	Aggregated Age/Sex: <15 Female	2,602
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	62,974
	Sum of Aggregated Age/Sex <15	5,218
	Sum of Aggregated Age/Sex 15+	98,893
	Sum of Aggregated Age/Sex disaggregates	104,111
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
Age/Sex: 20-24 Female		
Age/Sex: 25-49 Female		





	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,996
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	405
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	5,066
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	433
Aggregated Grouping by Age/Sex: 15+ Female	9,068	
Sum of Aggregated Age/Sex	14,972	



	disaggregates	
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	84,547
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	95,954
	Numerator: Indication: Routine	70,347
	Numerator: Indication: Targeted	13,849
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	



	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	



	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	79,821
	Denominator: Indication: Targeted	16,121
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	



	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	



	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	



	Numerator Aggregated Age/Sex: <15 Male	2,251
	Numerator Aggregated Age/Sex: 15+ Male	29,230
	Numerator Aggregated Age/Sex: <15 Female	2,212
	Numerator Aggregated Age/Sex: 15+ Female	50,853
	Denominator Aggregated Age/Sex: <15 Male	2,552
	Denominator Aggregated Age/Sex: 15+ Male	33,081
	Denominator Aggregated Age/Sex: <15 Female	2,498
	Denominator Aggregated Age/Sex: 15+ Female	57,822
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,502
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,105
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 1-9 (Numerator: Number	



	of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults and	





	children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of	



	<p>adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,</p>	



	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	264
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and	3,646



	children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	298
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,267
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	296
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,880
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	323



	those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,605
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	515
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	515
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	500
	CD4: Number of laboratories that perform this testing	76
	CD4: Number of laboratories that participate in this PT program	76
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	70
	Early infant diagnostics: Number of laboratories that perform this testing	6



	Early infant diagnostics: Number of laboratories that participate in this PT program	6
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	6
	HIV viral load: Number of laboratories that perform this testing	9
	HIV viral load: Number of laboratories that participate in this PT program	9
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	204
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	204
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	190
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	18
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that	0



	achieve acceptable successful passing criteria in this PT program	
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	3
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	3
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	
	Number of HIV Test Kits purchased	22,128
	Number of HIV CD4 Reagents purchased	931
	Number of Condoms purchased	
	Number of HIV Viral Load Reagents purchased	10,437
	Number of HIV ARVs purchased	1,535,859
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	1,794,402
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	189,015
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	6,402,172
	Condoms: Dollars planned (COP)/ spent (Actual)	476,443
	HIV ARVs: Dollars planned (COP)/	



Approved



	spent (Actual)	
--	----------------	--



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10954	Drew University	University	U.S. Department of Defense	GHP-State	0
10981	United Nations High Commissioner for Refugees	Multi-lateral Agency	U.S. Department of State/Bureau of Population, Refugees, and Migration	GHP-State	216,717
13598	JHPIEGO	University	U.S. Department of Defense	GHP-State	0
16857	African Evangelistic Enterprise	FBO	U.S. Agency for International Development	GHP-State	845,040
16858	Caritas Rwanda	FBO	U.S. Agency for International Development	GHP-State	505,050
16859	Society for Family Health	NGO	U.S. Agency for International Development	GHP-State	0
16860	François Xavier Bagnoud	NGO	U.S. Agency for International Development	GHP-State	454,680
17616	CHF International	NGO	U.S. Agency for International Development	GHP-State	4,340,700
17618	Society for Family Health	NGO	U.S. Department of Defense	GHP-State	405,499
17619	Emory University	University	U.S. Department	GHP-State	981,819



			of Health and Human Services/Centers for Disease Control and Prevention		
17623	Ministry of Health, Rwanda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	17,604,259
17625	Ministry of Health, Rwanda	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,384,795
18418	TBD	TBD	Redacted	Redacted	Redacted
18422	TBD	TBD	Redacted	Redacted	Redacted
18426	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	28,023,501
18432	Public Health Institute	NGO	U.S. Agency for International Development	GHP-State	1



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 10954</b>	<b>Mechanism Name: CDU Rwanda</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Drew University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 10954</b>			
<b>Mechanism Name: CDU Rwanda</b>			
<b>Prime Partner Name: Drew University</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	By: Known positives at entry	0
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	0



HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	0
HTC_TST_DSD	Service Delivery Point (Facility): VCT	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0
PMTCT_EID_DSD	Sum of Infant Age disaggregates	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0

**Implementing Mechanism Details**

<b>Mechanism ID: 10981</b>	<b>Mechanism Name: UNHCR</b>
Funding Agency: State/PRM	Procurement Type: Grant
Prime Partner Name: United Nations High Commissioner for Refugees	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 216,717</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 216,717</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	216,717

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	75,000
Key Populations: FSW	5,000
Focus Area:	Implementation of core HIV prevention interventions



	for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	15,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Post GBV Care
Sub Area:	Implementation

**Budget Code Information**

<b>Mechanism ID: 10981</b>			
<b>Mechanism Name: UNHCR</b>			
<b>Prime Partner Name: United Nations High Commissioner for Refugees</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	11,126	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	11,126	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	3,108	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	35,834	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	44,079	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	17,144	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	89,007	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	5,293	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,614
PMTCT_ART_DSD	New on ART	11
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	26
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,614
PMTCT_STAT_DSD	Number of new ANC and L&D clients	1,646
PMTCT_STAT_DSD	By: Known positives at entry	31
PMTCT_STAT_DSD	By: Number of new positives identified	8
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	39
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,000
PP_PREV_DSD	Total number of people in the target population	3,973
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	0
PP_PREV_DSD	Aggregated Age/sex: <15 Female	761
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,239
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions	65





	that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	Total estimated number of key population in the catchment area	85
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	65
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs	0



	(Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	85
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for	8,163



	HIV and received their test results during the past 12 months	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	681
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,985
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	580
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,914
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,261
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,899
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	8,160
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	12
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	1
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	24
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	40
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	643
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	2,191
HTC_TST_DSD	Service Delivery Point (Facility): VCT	2,905
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	2,289
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	35
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	60
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	35

TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	35
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	24
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	1



	TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	490
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	14
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	163
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	11
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	302
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	43
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	43
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	32
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	13
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	26
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	1
PMTCT_EID_DSD	Sum of Infant Age disaggregates	27
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	466
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	14
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	164
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	15
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	306
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	29



TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	470
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	499
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	50
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	17
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	31
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	48
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	396
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	451
TX_PVLS_DSD	Numerator: Indication: Routine	329
TX_PVLS_DSD	Numerator: Indication: Targeted	67
TX_PVLS_DSD	Denominator: Indication: Routine	375
TX_PVLS_DSD	Denominator: Indication: Targeted	77
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	12
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	131
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	11
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	243
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	14
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	148
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	12
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	276
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	37
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	40



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	25

### Implementing Mechanism Details

<b>Mechanism ID: 13598</b>	<b>Mechanism Name: JHPIEGO Rwanda</b>
----------------------------	---------------------------------------



Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 485,345</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 485,345</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b> 13598			
<b>Mechanism Name:</b> JHPIEGO Rwanda			
<b>Prime Partner Name:</b> JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	31,180





VMMC_CIRC_DSD	By Age: 10-14	2,120
VMMC_CIRC_DSD	By Age: 15-19	12,113
VMMC_CIRC_DSD	By Age: 20-24	9,651
VMMC_CIRC_DSD	By Age: 25-29	4,053
VMMC_CIRC_DSD	By Age: 30-49	3,118
VMMC_CIRC_DSD	By Age: 50+	125
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	24,009
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	31,180
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	9,354
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	21,826
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,180
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,610
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29,570
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,610
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	29,570
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	31,180
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	2
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	29
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	31,180

### Implementing Mechanism Details

<b>Mechanism ID: 16857</b>	<b>Mechanism Name: Ubaka Ejo</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Evangelistic Enterprise	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 845,040</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 845,040</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	845,040

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	100,000
Economic Strengthening	150,000
Education	100,000
Water	46,912
Gender: GBV	35,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: Gender Equality	25,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b> 16857			
<b>Mechanism Name:</b> Ubaka Ejo			
<b>Prime Partner Name:</b> African Evangelistic Enterprise			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	109,855	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	654,483	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	50,702	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	24,144
OVC_SERV_DSD	Age/Sex: 18+ Male	5,503
OVC_SERV_DSD	Age/Sex: 18+ Female	7,575
OVC_SERV_DSD	Sum of Age/Sex disaggregates	13,078
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,954
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	6,112

### Implementing Mechanism Details

<b>Mechanism ID: 16858</b>	<b>Mechanism Name: Gimbuka</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Caritas Rwanda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 505,050</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 505,050</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	505,050

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	55,776
Food and Nutrition: Policy, Tools, and Service Delivery	20,000
Economic Strengthening	80,000
Education	85,000
Water	35,736



Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	15,664
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	<b>16858</b>
----------------------	--------------



<b>Mechanism Name:</b>	Gimbuka		
<b>Prime Partner Name:</b>	Caritas Rwanda		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	50,505	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	404,242	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	30,303	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	20,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,201
OVC_SERV_DSD	Age/Sex: 18+ Male	3,440
OVC_SERV_DSD	Age/Sex: 18+ Female	6,448
OVC_SERV_DSD	Sum of Age/Sex disaggregates	9,888
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,023
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	6,290

### Implementing Mechanism Details

<b>Mechanism ID: 16859</b>	<b>Mechanism Name: Rwanda Social Marketing Program</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 557,652</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 557,652</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	16859		
<b>Mechanism Name:</b>	Rwanda Social Marketing Program		
<b>Prime Partner Name:</b>	Society for Family Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,396



PP_PREV_DSD	Total number of people in the target population	3,396
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	2,185
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	1,211
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	5,080
KP_PREV_DSD	Total estimated number of key population in the catchment area	5,080
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	196
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,884
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	196
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	4,884
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,841
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	943





HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,898
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,841
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,841
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	34
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	322
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	6,841

### Implementing Mechanism Details

<b>Mechanism ID: 16860</b>	<b>Mechanism Name: Turengere Abana</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: François Xavier Bagnoud	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 454,680</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 454,680</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	454,680

### Cross-Cutting Budget Attribution(s)



Human Resources for Health	60,000
Economic Strengthening	75,000
Education	70,000
Water	25,000
Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Food and Nutrition: Policy, Tools, and Service Delivery	20,000
Gender: Gender Equality	15,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



### Budget Code Information

<b>Mechanism ID:</b> 16860			
<b>Mechanism Name:</b> Turengere Abana			
<b>Prime Partner Name:</b> François Xavier Bagnoud			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	63,655	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	324,642	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	36,374	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,009	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,104
OVC_SERV_DSD	Age/Sex: 18+ Male	268
OVC_SERV_DSD	Age/Sex: 18+ Female	332



OVC_SERV_DSD	Sum of Age/Sex disaggregates	600
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	4,350
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,154

### Implementing Mechanism Details

<b>Mechanism ID: 17616</b>	<b>Mechanism Name: Twiyubake</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: CHF International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,340,700</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,340,700</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,340,700

### Cross-Cutting Budget Attribution(s)

Food and Nutrition: Policy, Tools, and Service Delivery	100,000
Economic Strengthening	1,500,000
Education	500,000
Gender: GBV	180,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Water	65,000
Gender: Gender Equality	15,000



Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	17616		
<b>Mechanism Name:</b>	Twiubake		
<b>Prime Partner Name:</b>	CHF International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	209,426	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HKID	3,911,053	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	130,221	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	90,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	66,780
OVC_SERV_DSD	Age/Sex: 18+ Male	10,016
OVC_SERV_DSD	Age/Sex: 18+ Female	10,022
OVC_SERV_DSD	Sum of Age/Sex disaggregates	20,038
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	23,376
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	23,366

### Implementing Mechanism Details

<b>Mechanism ID: 17618</b>	<b>Mechanism Name: SFH Rwanda</b>
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Society for Family Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 405,499</b>	
-------------------------------------------	--



<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 405,499</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	405,499

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	101,375
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID: 17618</b>			
<b>Mechanism Name: SFH Rwanda</b>			
<b>Prime Partner Name: Society for Family Health</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	273,001	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	132,498	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2017</b>
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,000



PP_PREV_DSD	Total number of people in the target population	6,000
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	4,000
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,000
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	200
KP_PREV_DSD	Total estimated number of key population in the catchment area	200
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	200
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	200
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	25,092
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,021
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	16,727
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	87
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	7,257
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,108
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	23,984
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	25,092
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	16
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+	104





	Male	
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	20
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	528
HTC_TST_DSD	Service Delivery Point (Community): Index testing	3,011
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	22,081

### Implementing Mechanism Details

<b>Mechanism ID: 17619</b>	<b>Mechanism Name: Implementing Evidence-Based Prevention Intervention for Key Populations in Republic of Rwanda under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Emory University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 981,819</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 981,819</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	981,819

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	249,450
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information



Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	178,066
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	24,700
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	24,700
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	17619		
<b>Mechanism Name:</b>	Implementing Evidence-Based Prevention Intervention for Key		
<b>Prime Partner Name:</b>	Populations in Republic of Rwanda under PEPFAR		
	Emory University		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	39,003	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	415,340	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVOP	527,476	0
------------	------	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,499
PP_PREV_DSD	Total number of people in the target population	2,499
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	0
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	2,499
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,966
KP_PREV_DSD	Total estimated number of key population in the catchment area	3,966
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	541
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV	0



	preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,425
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	541
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Transgender who are sex	0



	workers (Denominator: Total estimated number of key population in the catchment area)	
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	3,425
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	20,767
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,382
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,385
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	20,767
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	20,767
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	393
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	691
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	20,767
HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,026

### Implementing Mechanism Details

<b>Mechanism ID: 17623</b>	<b>Mechanism Name: Strengthening HIV Clinical</b>
----------------------------	---------------------------------------------------



	<b>Services in the Republic of Rwanda under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Rwanda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 17,604,259</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 17,604,259</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	17,604,259

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	8,540,000
Food and Nutrition: Policy, Tools, and Service Delivery	40,600
Key Populations: MSM and TG	25,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Key Populations: FSW	35,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	80,000



Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID:</b>	17623		
<b>Mechanism Name:</b>	Strengthening HIV Clinical Services in the Republic of Rwanda under		
<b>Prime Partner Name:</b>	PEPFAR Ministry of Health, Rwanda		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	1,407,170	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	691,667	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	239,817	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMIN	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>





Prevention	HVCT	2,017,295	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,607,785	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	10,281,560	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	1,358,965	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	130,361
PMTCT_ART_DSD	New on ART	1,137
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,464
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	130,361
PMTCT_STAT_DSD	Number of new ANC and L&D clients	132,986
PMTCT_STAT_DSD	By: Known positives at entry	2,712
PMTCT_STAT_DSD	By: Number of new positives identified	1,068
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,780
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	47,967
VMMC_CIRC_DSD	By Age: 15-19	16,792



VMMC_CIRC_DSD	By Age: 20-24	15,822
VMMC_CIRC_DSD	By Age: 25-29	15,345
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	32,614
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	47,959
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	23,881
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	23,884
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	852,880
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	34,548
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	337,049
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	37,927
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	445,500
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	72,475
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	782,549
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	855,024
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	139
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	3,561
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	164
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	6,065
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	49,446
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	13,978
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	214,438
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0



HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	103,836
HTC_TST_DSD	Service Delivery Point (Facility): VCT	280,668
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	37,311
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	130,284
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	2,584
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	5,369
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,567
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,567
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,594
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	43
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	852
GEND_GBV_DSD	Number of people receiving post-GBV care	5,789
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,679
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	4,108
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,332
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	873
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	873



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	554
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	296
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	98,677
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,555
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	32,979
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,525
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	60,621
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	8,881
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	8,871
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	6,393
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,485
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,429



PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	194
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,623
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	43
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	100,794
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,581
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	33,737
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,573
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	61,927
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,154
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	95,664
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	100,818
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,752
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	404
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,899
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	432
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	8,995
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	14,730
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	81,642
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	92,709
TX_PVLS_DSD	Numerator: Indication: Routine	67,760
TX_PVLS_DSD	Numerator: Indication: Targeted	13,531
TX_PVLS_DSD	Denominator: Indication: Routine	76,931



TX_PVLS_DSD	Denominator: Indication: Targeted	15,765
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	2,218
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	27,222
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,187
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	50,013
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	2,517
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	30,916
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,472
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	56,805
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	10,293
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,873
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	263
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,498
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	297
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,209
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	295
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	3,717



	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	322
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,540

**Implementing Mechanism Details**

<b>Mechanism ID: 17625</b>	<b>Mechanism Name: Implementing Technical and Science Support Services (TSSS) in the Republic of Rwanda under PEPFAR</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health, Rwanda	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 4,384,795</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,384,795</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,384,795

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	1,355,067
----------------------------	-----------



**Budget Code Information**

<b>Mechanism ID:</b>	17625		
<b>Mechanism Name:</b>	Implementing Technical and Science Support Services (TSSS) in the		
<b>Prime Partner Name:</b>	Republic of Rwanda under PEPFAR		
<b>Prime Partner Name:</b>	Ministry of Health, Rwanda		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	206,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	288,400	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	206,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	1,131,461	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,193,334	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	164,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	41,200	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0





Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	61,800	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	206,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	618,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	267,800	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	515
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	515
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	500
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	76
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	76
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	70
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	6
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	6
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that	6



	achieve acceptable successful passing criteria in this PT program	
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	9
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	9
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	204
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	204
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	190
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	18
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	0
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	3
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	3
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2

**Implementing Mechanism Details**

<b>Mechanism ID: 18418</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



**Implementing Mechanism Details**

<b>Mechanism ID: 18422</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18426</b>	<b>Mechanism Name: Global Health Supply Chain Program</b>	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Global Health Supply Chain Program		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
G2G: No	Managing Agency:	

<b>Total All Funding Sources: 28,023,501</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 28,023,501</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	28,023,501

**Cross-Cutting Budget Attribution(s)**

Key Populations: MSM and TG	153,451
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	824,631
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs



**Budget Code Information**

<b>Mechanism ID:</b> 18426			
<b>Mechanism Name:</b> Global Health Supply Chain Program			
<b>Prime Partner Name:</b> Global Health Supply Chain Program			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	798,686	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	213,031	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	362,568	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,529,384	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	225,870	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,199,377	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	476,443	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	204,135	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	16,284,488	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	6,392,703	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	336,816	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
INVS_COMD	Number of HIV Test Kits purchased	22,128
INVS_COMD	Number of HIV CD4 Reagents purchased	931
INVS_COMD	Number of HIV Viral Load Reagents purchased	10,437
INVS_COMD	Number of HIV ARVs purchased	1,535,859
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	1,794,402
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	189,015
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	6,402,172
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	476,443

### Implementing Mechanism Details

<b>Mechanism ID: 18432</b>	<b>Mechanism Name: Global Health Fellows Program - II</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Public Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1</b>	
Funding Source	Funding Amount
GHP-State	1



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 18432			
<b>Mechanism Name:</b> Global Health Fellows Program - II			
<b>Prime Partner Name:</b> Public Health Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Agency Information - Costs of Doing Business**

**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		60,231		204,669	60,231	264,900
ICASS		604,626		5,374	604,626	610,000
Institutional Contractors		97,597		192,402	97,597	289,999
Management		44,692		335,808	44,692	380,500



Meetings/Professional Development						
Non-ICASS Administrative Costs		53,545		2,755	53,545	56,300
Staff Program Travel		13,755		23,244	13,755	36,999
USG Staff Salaries and Benefits - Internationally Recruited		94,720		372,678	94,720	467,398
USG Staff Salaries and Benefits - Locally Recruited		30,833		866,514	30,833	897,347
<b>Total</b>	<b>0</b>	<b>999,999</b>	<b>0</b>	<b>2,003,444</b>	<b>999,999</b>	<b>3,003,443</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		0		4,000	0	4,000
ICASS		0		35,000	0	35,000
Non-ICASS		0		6,000	0	6,000



Administrative Costs						
Staff Program Travel				70,000	0	70,000
USG Staff Salaries and Benefits - Locally Recruited				160,000	0	160,000
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>275,000</b>	<b>0</b>	<b>275,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		0		863,351	0	863,351
Computers/IT Services		215,261		0	215,261	215,261
ICASS		1,250,000		0	1,250,000	1,250,000
Institutional Contractors				546,079	0	546,079
Management Meetings/Professional Development		0		38,000	0	38,000
Non-ICASS		0		120,480	0	120,480





Administrative Costs						
Non-ICASS Motor Vehicles		26,521		0	26,521	26,521
Staff Program Travel	0	0		295,253	0	295,253
USG Staff Salaries and Benefits - Internationally Recruited	1,440,625	1,072,385		0	2,513,010	2,513,010
USG Staff Salaries and Benefits - Locally Recruited	0	1,537,117		92,709	1,537,117	1,629,826
<b>Total</b>	<b>1,440,625</b>	<b>4,101,284</b>	<b>0</b>	<b>1,955,872</b>	<b>5,541,909</b>	<b>7,497,781</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Staff Program Travel		35,000		0	35,000	35,000
USG Staff Salaries and Benefits - Internationally		98,004		0	98,004	98,004

Approved



Recruited						
<b>Total</b>	<b>0</b>	<b>133,004</b>	<b>0</b>	<b>0</b>	<b>133,004</b>	<b>133,004</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Non-ICASS Administrative Costs		0		243,923	0	243,923
Staff Program Travel				31,140	0	31,140
USG Staff Salaries and Benefits - Locally Recruited				222,618	0	222,618
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>497,681</b>	<b>0</b>	<b>497,681</b>